Gastrointestinal Cancer
Molecular Profiling Is a Necessity in Colorectal Cancer Treatment
August 09, 2022
Article
At the 6th Annual SONO meeting, Kelley A. Rone, DNP, RN, AGNP-C, reviewed evidence supporting molecular testing in patients with colorectal cancer.
Rone Discusses Exciting Immunotherapy Research in Gastrointestinal Cancer
August 02, 2022
Article
Kelley A. Rone, DNP, RN, ADNP-c, highlights the pivotal trials assessing the role of immunotherapy in gastrointestinal cancer and what the findings may mean for oncology nurses.
Oncology Nursing News Top Stories: July 2022
July 29, 2022
Article
Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from July 2022.
Kelley Rone on the Evolving Role of Immunotherapy in GI Cancers
July 28, 2022
Video
Kelley A. Rone, DNP, RN, AGNP-c, discusses the advantages associated with immunotherapy in the treatment of patients with gastrointestinal cancers.
Ripretinib Exhibits Better Tolerability Profile Vs Sunitinib in Advanced GIST Tumors
July 27, 2022
Article
An analysis of patient-reported outcomes from the phase 3, INTRIGUE trial (NCT03673501) showed that ripretinib had a more tolerable safety profile than sunitinib in treating patients with advanced GIST tumors.
ESMO Guideline on Liquid Biopsy Address Quality Standards for Clinical Implementation
July 27, 2022
Article
In early-stage cancers, ctDNA has a role in screening, neoadjuvant monitoring, identification of molecular residual disease (MRD), molecular relapse monitoring, and early assessment of treatment response.
Uniform Baseline Measurements Are Crucial in Improving Standard of Supportive Care
July 26, 2022
Article
Lidia Schapira, MD, FASCO, discusses the importance of rigorous baseline measurement in improving the assessment and management of distressful cancer symptoms.
Tremelimumab Plus Durvalumab Bests Sorafenib OS Rates In Frontline HCC Treatment
July 17, 2022
Article
Arndt Vogel, MD, PhD, discusses a post-hoc analysis of the phase 3 HIMALAYA trial which found tremelimumab plus durvalumab to be superior to sorafenib in improving overall survival.
Key Advances in Cancer Survivorship Toxicity Management
July 15, 2022
Podcast
In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.
Targeting KRAS Mutations May Help Address Unmet Need in Pancreatic Cancer Treatment
July 12, 2022
Article
An expert of oncology and pharmacology with the Barbara Ann Karmanos Cancer Institute discusses the developing presence of targeted treatments in the pancreatic cancer treatment paradigm.